Detection of C-peptide in Youth With Longstanding Type 1 Diabetes Mellitus

Mount Sinai Health System

Status: Completed

Conditions: Type 1 Diabetes Mellitus

Treatments: Dietary Supplement: Boost shake

Study type: Observational

Funder types: Other

Identifiers

NCT02131675

GCO 12-1425

Details and patient eligibility

About

Background Type 1 diabetes is characterized by pancreatic beta-cell destruction and an inability to synthesize insulin. Connecting peptide (C-peptide) is formed from the same precursor as insulin and is produced in equimolar amounts as insulin. There are several clinical trials currently being performed to explore the possibility of beta-cell preservation or regeneration. Most children are not eligible for these trials because it is often presumed that C-peptide levels will decrease and become undetectable after years of having type 1 diabetes. Several studies in the adult population have demonstrated that C-peptide may remain measureable in patients who have had diabetes for up to 50 years after diagnosis. Recently, it was demonstrated that 10% of adult patients who have had type 1 diabetes for 31-40 years have measureable levels of serum C-peptide if measured with an ultrasensitive assay. The levels were lower in patients who had diabetes for a longer time. This pattern was also demonstrated in the Diabetes Control and Complications Trial (DCCT) and NHANES trial. No studies have been performed exclusively in pediatric patients Hypothesis The investigators hypothesize that C-peptide should be detectable in the sera of pediatric patients who have had type 1 diabetes for greater than 1 year and as far out as > 20 years after diagnosis. The investigators also hypothesize that since their patient population has had diabetes for less time as compared to adults, the levels of C-peptide should be higher than reported for adults and that a greater proportion of patients in the pediatric population will have detectable C-peptide levels as compared to adults.

Full description

1. Objectives:

1. To determine if C-peptide is detectable in the sera of children that have had type 1 diabetes for more than 1 year using an ultrasensitive assay.
2. To correlate C-peptide levels with duration since diagnosis, current age, antibody titers at diagnosis, hemoglobin A1c, total daily insulin dosage.
3. To determine responsiveness of residual C-peptide to mixed-meal testing.

Enrollment: 50 patients

Sex: All

Ages: 1 to 21 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female
• 1-25 years of age
• Have had type 1 diabetes for more than 1 year.

Exclusion criteria

• Does not meet inclusion criteria
• Foster children
• Patients without primary caregiver
• Pregnant

Trial design

50 participants in 1 patient group

Boost shake

Description:

children that have had type 1 diabetes for more than 1 year

Treatment:

Dietary Supplement: Boost shake